Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial

References

• Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM, Jahanshahi-Anbuhi S. Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 2021;34. doi:10.1128/CMR.00228-20.
   PubMed Web of Science ®Google Scholar
• Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–11. doi:10.1038/s41579-020-00459-7.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Coronavirus diseases (COVID-19) situation dashboard. [accessed 2023 Oct 28]. https://covid19.who.int/.
   Google Scholar
• Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, Wellington E, Khawam J, Munro K, Cole M. et al. Protection against SARS-CoV-2 after covid-19 vaccination and previous infection. N Engl J Med. 2022;386(13):1207–20. doi:10.1056/NEJMoa2118691.
   PubMed Web of Science ®Google Scholar
• Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28:202–21. doi:10.1016/j.cmi.2021.10.005.
   PubMed Web of Science ®Google Scholar
• Hwang JH, You YS, Yeom SW, Lee MG, Lee JH, Kim MG Kim JS. et al. Influenza viral infection is a risk factor for severe illness in COVID-19 patients: a nationwide population-based cohort study. Emerging Microbes Infect. 2023;12:2164215. doi:10.1080/22221751.2022.2164215.
   PubMed Web of Science ®Google Scholar
• Talbot HK, Martin ET, Gaglani M, Middleton DB, Ghamande S, Silveira FP, Murthy K, Zimmerman RK, Trabue CH, Olson SM. et al. Coronavirus disease 2019 (COVID-19) versus influenza in hospitalized adult patients in the United States: differences in demographic and severity indicators. Clin Infect Dis. 2021;73(12):2240–7. doi:10.1093/cid/ciab123.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet (London, Engl). 2018;391:1285–300. doi:10.1016/S0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Javanian M, Barary M, Ghebrehewet S, Koppolu V, Vasigala V, Ebrahimpour S. A brief review of influenza virus infection. J Med Virol. 2021;93(8):4638–46. doi:10.1002/jmv.26990.
   PubMed Web of Science ®Google Scholar
• Keshavarz M, Mirzaei H, Salemi M, Momeni F, Mousavi MJ, Sadeghalvad M, Arjeini Y, Solaymani‐Mohammadi F, Sadri Nahand J, Namdari H. et al. Influenza vaccine: Where are we and where do we go? Rev Med Virol. 2019;29:e2014. doi:10.1002/rmv.2014.
   PubMed Web of Science ®Google Scholar
• Wang R, Liu M, Liu J. The association between Influenza Vaccination and COVID-19 and its outcomes: a systematic review and meta-analysis of observational studies. Nato Adv Sci Inst Se. 2021;9(5):529. doi:10.3390/vaccines9050529.
   Google Scholar
• Razzaghi H, Srivastav A, de Perio MA, Laney AS, Black CL. Influenza and COVID-19 vaccination coverage among health care personnel - United States, 2021-22. MMWR Morb Mortal Wkly Rep. 2022;71:1319–26. doi:10.15585/mmwr.mm7142a2.
   PubMed Web of Science ®Google Scholar
• US Centers for Disease Control and Prevention. Interim clinical consideration for use of COVID-19 vaccines currently approved or authorized in the United States. [accessed 2023 Oct 28]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.
   Google Scholar
• Department of Health and Aged Care (Australia). Australian government department of health early advice on 2021 influenza vaccination. [accessed 2023 Oct 28]. https://www.health.gov.au/news/early-advice-on-2021-influenza-vaccination.
   Google Scholar
• Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B. et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdox1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet (London, Engl). 2021;398:2277–87. doi:10.1016/S0140-6736(21)02329-1.
   PubMed Web of Science ®Google Scholar
• WHO. Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance. [accessed 2023 Oct 28]. https://apps.who.int/iris/bitstream/handle/10665/346897/WHO-2019-nCoV-SAGE-Vaccines-coadministration-Influenza-2021.1-eng.pdf?sequence=1&isAllowed=y.
   Google Scholar
• Plotkin SA. Vaccines: past, present and future. Nat Med. 2005;11(4 Suppl):S5–11. doi:10.1038/nm1209.
   PubMed Web of Science ®Google Scholar
• Nascimento IP, Leite LC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res. 2012;45(12):1102–11. doi:10.1590/S0100-879X2012007500142.
   PubMed Web of Science ®Google Scholar
• Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, Edelman J, Smolenov I. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine. 2020;38(2):242–50. doi:10.1016/j.vaccine.2019.10.021.
   PubMed Web of Science ®Google Scholar
• WHO. 2019. Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual for the revised WHO classification, 2nd ed. [accessed 2023 Oct 20]. https://www.who.int/publications/i/item/9789241516990.
   Google Scholar
• Chotpitayasunondh T, Fischer TK, Heraud JM, Hurt AC, Monto AS, Osterhaus A, Shu Y, Tam JS. Influenza and COVID-19: What does co-existence mean? Influenza and other respiratory viruses. Influenza Other Respi Viruses. 2021;15(3):407–12. doi:10.1111/irv.12824.
   PubMed Web of Science ®Google Scholar
• Flerlage T, Boyd DF, Meliopoulos V, Thomas PG, Schultz-Cherry S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat Rev Microbiol. 2021;19(7):425–41. doi:10.1038/s41579-021-00542-7.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Y, Zhang X, Liu L. Influenza and universal vaccine research in China. Viruses. 2022;15(1):15. doi:10.3390/v15010116.
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45. doi:10.1001/jama.2021.8565.
   PubMed Web of Science ®Google Scholar
• Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, Rajaram S, Graves-Jones A, Edelman J, Burns F. et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(2):167–79. doi:10.1016/S2213-2600(21)00409-4.
   PubMed Web of Science ®Google Scholar
• Chen H, Huang Z, Chang S, Hu M, Lu Q, Zhang Y, Wang H, Xiao Y, Wang H, Ge Y. et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial. Vaccine. 2022;40(36):5322–32. doi:10.1016/j.vaccine.2022.07.033.
   PubMed Web of Science ®Google Scholar
• Shenyu W, Xiaoqian D, Bo C, Xuan D, Zeng W, Hangjie Z, Qianhui Z, Zhenzhen L, Chuanfu Y, Juan Y. et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: a randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China. Vaccine. 2022;40(36):5356–65. doi:10.1016/j.vaccine.2022.07.021.
   PubMed Web of Science ®Google Scholar
• Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, Pandey A, Perez L, Sater N, Shrestha A. et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022;10(4):392–402. doi:10.1016/S2213-2600(21)00557-9.
   PubMed Web of Science ®Google Scholar